Literature DB >> 15604425

Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon.

Nathalie Desloges1, Markus Rahaus1, Manfred H Wolff1.   

Abstract

Varicella-zoster virus (VZV) is sensitive to type I and type II interferons (IFNs), which mediate antiviral effects. In this study, it was demonstrated that IFN-beta and IFN-gamma inhibited the replication of VZV in vitro. Although IFN-beta was more effective than IFN-gamma, the level of inhibition of VZV replication achieved by the combination of both IFNs was more than additive and it was concluded that these two cytokines acted synergistically. Expression of the IFN-induced, double-stranded RNA-activated protein kinase PKR and its phosphorylation level were not modulated strongly during ongoing replication of VZV. However, in the presence of IFN-beta, but not IFN-gamma, PKR expression and its phosphorylation were increased, explaining in part the inhibition of virus replication by IFNs. The expression of herpes simplex virus Us11, a viral protein with several functions, including prevention of PKR activation, strongly increased the level of VZV replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15604425     DOI: 10.1099/vir.0.80466-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3.

Authors:  Huifang Zhu; Chunfu Zheng; Junji Xing; Shuai Wang; Shuping Li; Rongtuan Lin; Karen L Mossman
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Beta interferon and gamma interferon synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells.

Authors:  Amy T Pierce; Joanna DeSalvo; Timothy P Foster; Athena Kosinski; Sandra K Weller; William P Halford
Journal:  J Gen Virol       Date:  2005-09       Impact factor: 3.891

Review 3.  Varicella zoster virus immune evasion strategies.

Authors:  Allison Abendroth; Paul R Kinchington; Barry Slobedman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

4.  OAS and PKR are not required for the antiviral effect of Ad:IFN-gamma against acute HSV-1 in primary trigeminal ganglia cultures.

Authors:  Bobbie Ann Austin; William Halford; Robert H Silverman; Bryan R G Williams; Daniel J J Carr
Journal:  J Interferon Cytokine Res       Date:  2006-04       Impact factor: 2.607

5.  Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.

Authors:  Mauro Pires Moraes; Teresa de Los Santos; Marla Koster; Traci Turecek; He Wang; Vladimir G Andreyev; Marvin J Grubman
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

6.  Autophagy and the effects of its inhibition on varicella-zoster virus glycoprotein biosynthesis and infectivity.

Authors:  Erin M Buckingham; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

7.  The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts.

Authors:  Eric Bartee; Mohamed R Mohamed; M Cecilia Lopez; Henry V Baker; Grant McFadden
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

Review 8.  Cytokine synergy: an underappreciated contributor to innate anti-viral immunity.

Authors:  Eric Bartee; Grant McFadden
Journal:  Cytokine       Date:  2013-05-18       Impact factor: 3.861

9.  Double-stranded RNA-dependent protein kinase-dependent apoptosis induction by a novel small compound.

Authors:  Wenxian Hu; Wayne Hofstetter; Xiaoli Wei; Wei Guo; Yanbin Zhou; Abujiang Pataer; Hong Li; Bingliang Fang; Stephen G Swisher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-09       Impact factor: 4.030

10.  Varicella-Zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response.

Authors:  Aruna P N Ambagala; Jeffrey I Cohen
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.